Histological and electron microscopic features of the extracellular matrix of invasive breast ductal carcinoma of no special type. Report of 5 cases and literature review

References

• Parijatham ST. Diagnosis and management of high-risk breast lesions. J Natl Compr Canc Netw. 2018;16(11):1391–1396. doi:10.6004/JNCCN.2018.7099.
   PubMed Web of Science ®Google Scholar
• Brogi E, Krystel-Whittemore M. Papillary neoplasms of the breast including upgrade rates and management of intraductal papilloma without atypia diagnosed at core needle biopsy. Modern Pathol. 2020;34(1):1. doi:10.1038/s41379-020-00706-5.
   PubMedGoogle Scholar
• Coutant C, Canlorbe G, Bendifallah S, Beltjens F. Prise en charge des proliférations épithéliales du sein avec et sans atypies : hyperplasie canalaire atypique, métaplasie cylindrique avec atypie, néoplasies lobulaires, proliférations épithéliales sans atypie, mastopathie fibrokystique, adénose, cicatrices radiaires, mucocèles, lésions prolifératives apocrines : recommandations pour la pratique clinique. J Gynecol Obstet Biol Reprod (Paris). 2015;44(10):980–995. doi:10.1016/J.JGYN.2015.09.037.
   PubMedGoogle Scholar
• Solin LJ. Management of Ductal Carcinoma in situ (DCIS) of the breast: present approaches and future directions. Curr Oncol Rep. 2019;2121(4):4–81–8. doi:10.1007/S11912-019-0777-3.
   PubMed Web of Science ®Google Scholar
• Stachs A, Stubert J, Reimer T, Hartmann S. Benign breast disease in women. Dtsch Arztebl Int. 2019;116(33–34):565–573. doi:10.3238/ARZTEBL.2019.0565.
   PubMed Web of Science ®Google Scholar
• Thorat MA, Balasubramanian R. Breast cancer prevention in high-risk women. Best Pract Res Clin Obstet Gynaecol. 2020;65:18–31. doi:10.1016/J.BPOBGYN.2019.11.006.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kleer CG. Phyllodes tumor of the breast: histopathologic features, differential diagnosis, and molecular/genetic updates. Arch Pathol Lab Med. 2016;140(7):665–671. doi:10.5858/ARPA.2016-0042-RA.
   PubMed Web of Science ®Google Scholar
• Piersma B, Hayward MK, Weaver VM. Fibrosis and cancer: a strained relationship. Biochimica Et Biophysica Acta (BBA) - Reviews on Cancer. 2020;1873(2):188356. doi:10.1016/J.BBCAN.2020.188356.
   PubMed Web of Science ®Google Scholar
• Rakha EA, Miligy IM, Gorringe KL, et al. Invasion in breast lesions: the role of the epithelial–stroma barrier. Histopathology. 2018;72(7):1075–1083. doi:10.1111/HIS.13446.
   PubMed Web of Science ®Google Scholar
• Yu K, Rohr J, Liu Y, et al. Progress in triple negative breast carcinoma pathophysiology: potential therapeutic targets. Pathol Res Pract. 2020;216(4):152874. doi:10.1016/J.PRP.2020.152874.
   PubMed Web of Science ®Google Scholar
• Chen W, Wei W, Yu L, et al. Mammary development and breast cancer: a notch perspective. J Mammary Gland Biol Neoplasia. 2021;26(3):309–320. doi:10.1007/S10911-021-09496-1.
   PubMed Web of Science ®Google Scholar
• Makki J. Diversity of breast carcinoma: histological subtypes and clinical relevance. Clin Med Insights Pathol. 2015;8(1):23. doi:10.4137/CPATH.S31563.
   PubMedGoogle Scholar
• Cserni G. Histological type and typing of breast carcinomas and the WHO classification changes over time. Pathologica. 2020;112(1):25–41. doi:10.32074/1591-951X-1-20.
   PubMed Web of Science ®Google Scholar
• Chen H, Bai F, Wang M, Zhang M, Zhang P, Wu K. The prognostic significance of co-existence ductal carcinoma in situ in invasive ductal breast cancer: a large population-based study and a matched case-control analysis. Ann Transl Med. 2019;7(18):484. doi:10.21037/ATM.2019.08.16.
   PubMed Web of Science ®Google Scholar
• Kim M, Kim M, Chung YR, Park SY. Mammary carcinoma arising in microglandular adenosis: a report of five cases. J Pathol Transl Med. 2017;51(4):422–427. doi:10.4132/JPTM.2016.11.11.
   PubMedGoogle Scholar
• Scholl AR, Flanagan MB. Educational case: invasive ductal carcinoma of the breast. Acad Pathol. 2020;7:7. doi:10.1177/2374289519897390.
   Web of Science ®Google Scholar
• Zagelbaum NK, Ward MF, Okby N, Karpoff H. Invasive ductal carcinoma of the breast with osteoclast-like giant cells and clear cell features: a case report of a novel finding and review of the literature. World J Surg Oncol. 2016;14(1). doi:10.1186/S12957-016-0982-6.
   PubMedGoogle Scholar
• Fu Z, Song P, Li D, et al. Cancer-associated fibroblasts from invasive breast cancer have an attenuated capacity to secrete collagens. Int J Oncol. 2014;45(4):1479–1488. doi:10.3892/IJO.2014.2562/HTML.
   PubMed Web of Science ®Google Scholar
• Oskarsson T. Extracellular matrix components in breast cancer progression and metastasis. Breast. 2013;2(S2):S66–72. doi:10.1016/J.BREAST.2013.07.012.
   Google Scholar
• Giussani M, Landoni E, Merlino G, et al. Extracellular matrix proteins as diagnostic markers of breast carcinoma. J Cell Physiol. 2018;233(8):6280–6290. doi:10.1002/JCP.26513.
   PubMed Web of Science ®Google Scholar
• Cox TR, Erler JT. Molecular pathways: connecting fibrosis and solid tumor metastasis. Clin Cancer Res. 2014;20(14):3637–3643. doi:10.1158/1078-0432.CCR-13-1059.
   PubMed Web of Science ®Google Scholar
• Wyckoff JB, Wang Y, Lin EY, et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67(6):2649–2656. doi:10.1158/0008-5472.CAN-06-1823.
   PubMed Web of Science ®Google Scholar
• Egeblad M, Rasch MG, Weaver VM. Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol. 2010;22(5):697–706. doi:10.1016/J.CEB.2010.08.015.
   PubMed Web of Science ®Google Scholar
• Lindgren M, Jansson M, Tavelin B, Dirix L, Vermeulen P, Nyström H. Type IV collagen as a potential biomarker of metastatic breast cancer. Clin Exp Metastasis. 2021;38(2):175–185. doi:10.1007/S10585-021-10082-2.
   PubMed Web of Science ®Google Scholar
• Chang J, Chaudhuri O. Beyond proteases: basement membrane mechanics and cancer invasion. J Cell Biol. 2019;218(8):2456–2469. doi:10.1083/JCB.201903066.
   PubMed Web of Science ®Google Scholar
• Nyström H, Naredi P, Hafström L, Sund M. Type IV collagen as a tumour marker for colorectal liver metastases. Eur J Surg Oncol. 2011;37(7):611–617. doi:10.1016/J.EJSO.2011.04.010.
   PubMed Web of Science ®Google Scholar
• Dhakal HP, Bassarova A, Naume B, et al. Breast carcinoma vascularity: a comparison of manual microvessel count and Chalkley count. Histol Histopathol. 2009;24(8):1049–1059. doi:10.14670/HH-24.1049.
   PubMed Web of Science ®Google Scholar
• Senchukova MA, Nikitenko NV, Tomchuk ON, Zaitsev NV, Stadnikov AA. Different types of tumor vessels in breast cancer: morphology and clinical value. Springerplus. 2015;4(1). doi:10.1186/S40064-015-1293-Z.
   PubMedGoogle Scholar
• Kim J. Pericytes in breast cancer. Adv Exp Med Biol. 2019;1147:93–107. doi:10.1007/978-3-030-16908-4_3.
   PubMed Web of Science ®Google Scholar
• Coleman RE, Gregory W, Marshall H, Wilson C, Holen I. The metastatic microenvironment of breast cancer: clinical implications. Breast. 2013;2(S2):S50–56. doi:10.1016/J.BREAST.2013.07.010.
   Google Scholar
• Soysal SD, Tzankov A, Muenst SE. Role of the tumor microenvironment in breast cancer. Pathobiology. 2015;82(3–4):142–152. doi:10.1159/000430499.
   PubMed Web of Science ®Google Scholar
• Cowell CF, Weigelt B, Sakr RA, et al. Progression from ductal carcinoma in situ to invasive breast cancer: revisited. Mol Oncol. 2013;7(5):859–869. doi:10.1016/J.MOLONC.2013.07.005.
   PubMed Web of Science ®Google Scholar
• Folgueira MAAK, Maistro S, Katayama MLH, et al. Markers of breast cancer stromal fibroblasts in the primary tumour site associated with lymph node metastasis: a systematic review including our case series. Biosci Rep. 2013;33(6). doi:10.1042/BSR20130060.
   PubMedGoogle Scholar
• Nguyen M, Lee MC, Wang JL, et al. The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype. Oncogene. 2000;19(31):3449–3459. doi:10.1038/SJ.ONC.1203677.
   PubMed Web of Science ®Google Scholar
• Del Valle PR, Milani C, Brentani MM, et al. Transcriptional profile of fibroblasts obtained from the primary site, lymph node and bone marrow of breast cancer patients. Genet Mol Biol. 2014;37(3):480. doi:10.1590/S1415-47572014000400002.
   PubMed Web of Science ®Google Scholar
• Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335–348. doi:10.1016/J.CELL.2005.02.034.
   PubMed Web of Science ®Google Scholar
• Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin Cancer Biol. 2014;25:47–60. doi:10.1016/J.SEMCANCER.2014.01.005.
   PubMed Web of Science ®Google Scholar
• Pelon F, Bourachot B, Kieffer Y, et al. Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms. Nat Commun. 2020;11(1). doi:10.1038/S41467-019-14134-W.
   PubMed Web of Science ®Google Scholar
• Choi YP, Lee JH, Gao MQ, et al. Cancer-associated fibroblast promote transmigration through endothelial brain cells in three-dimensional in vitro models. Int J Cancer. 2014;135(9):2024–2033. doi:10.1002/IJC.28848.
   PubMed Web of Science ®Google Scholar
• Wen S, Hou Y, Fu L, et al. Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin β3–p38 MAPK signalling. Cancer Lett. 2019;442:320–332. doi:10.1016/J.CANLET.2018.10.015.
   PubMed Web of Science ®Google Scholar
• da Cunha A, Michelin MA, Murta EFC. Pattern response of dendritic cells in the tumor microenvironment and breast cancer. World J Clin Oncol. 2014;5(3):495. doi:10.5306/WJCO.V5.I3.495.
   PubMedGoogle Scholar
• Varikuti S, Singh B, Volpedo G, et al. Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells. Br J Cancer. 2020;122122(7):7–10131005–1013. doi:10.1038/s41416-020-0743-8.
   Web of Science ®Google Scholar
• Fainaru O, Almog N, Yung CW, et al. Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells. Faseb J. 2010;24(5):1411. doi:10.1096/FJ.09-147025.
   PubMed Web of Science ®Google Scholar
• Gardner A, Ruffell B. Dendritic cells and cancer immunity. Trends Immunol. 2016;37(12):855–865. doi:10.1016/J.IT.2016.09.006.
   PubMed Web of Science ®Google Scholar
• Michielsen AJ, Hogan AE, Marry J, et al. Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. PLoS One. 2011;6(11):e27944. doi:10.1371/JOURNAL.PONE.0027944.
   PubMed Web of Science ®Google Scholar
• Ning Y, Shen K, Wu Q, et al. Tumor exosomes block dendritic cells maturation to decrease the T cell immune response. Immunol Lett. 2018;199:36–43. doi:10.1016/J.IMLET.2018.05.002.
   PubMed Web of Science ®Google Scholar
• Chen X, Shao Q, Hao S, et al. CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function. Oncotarget. 2017;8(8):13703–13715. doi:10.18632/ONCOTARGET.14626.
   PubMedGoogle Scholar
• Obeid E, Nanda R, Fu YX, Olopade OI. The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol. 2013;43(1):5–12. doi:10.3892/ijo.2013.1938.
   PubMed Web of Science ®Google Scholar
• Qiu SQ, Waaijer SJH, Zwager MC, de Vries EGE, van der Vegt B, Schröder CP. Tumor-associated macrophages in breast cancer: innocent bystander or important player? Cancer Treat Rev. 2018;70:178–189. doi:10.1016/J.CTRV.2018.08.010.
   PubMed Web of Science ®Google Scholar
• Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;33(1):1–3523–35. doi:10.1038/nri978.
   Web of Science ®Google Scholar
• Jamiyan T, Kuroda H, Yamaguchi R, Abe A, Hayashi M. CD68- and CD163-positive tumor-associated macrophages in triple negative cancer of the breast. Virchows Archiv. 2020;477(6):767–775. doi:10.1007/s00428-020-02855-z.
   PubMed Web of Science ®Google Scholar
• Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86(5):1065–1073. doi:10.1189/JLB.0609385.
   PubMed Web of Science ®Google Scholar
• Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021;18(4):842–859. doi:10.1038/S41423-020-00565-9.
   PubMed Web of Science ®Google Scholar
• Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4(1). doi:10.1186/S40425-016-0165-6.
   Google Scholar
• Allen M, Jones JL. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol. 2011;223(2):163–177. doi:10.1002/PATH.2803.
   Web of Science ®Google Scholar
• Tanaka A, Sakaguchi S. Targeting Treg cells in cancer immunotherapy. Eur J Immunol. 2019;49(8):1140–1146. doi:10.1002/EJI.201847659.
   PubMed Web of Science ®Google Scholar
• Núñez NG, Tosello Boari J, Ramos RN, et al. Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients. Nat Commun. 2020;11(1). doi:10.1038/S41467-020-17046-2.
   Web of Science ®Google Scholar
• Infante M, Fabi A, Cognetti F, Gorini S, Caprio M, Fabbri A. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. J Exp Clin Cancer Res. 2019;38(1). doi:10.1186/S13046-018-1001-2.
   Google Scholar
• van Dam PA, Verhoeven Y, Trinh XB, et al. RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol. 2019;133:85–91. doi:10.1016/J.CRITREVONC.2018.10.011.
   PubMed Web of Science ®Google Scholar
• Del Alcazar CRG, Alečkovic M, Polyak K. Immune escape during breast tumor progression. Cancer Immunol Res. 2020;8(4):422–427. doi:10.1158/2326-6066.CIR-19-0786.
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–1570. doi:10.1126/SCIENCE.1203486.
   PubMed Web of Science ®Google Scholar
• Wu SY, Fu T, Jiang YZ, Shao ZM. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1). doi:10.1186/S12943-020-01238-X.
   Web of Science ®Google Scholar
• Nascimento C, Ferreira F. Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model. Biochimica Et Biophysica Acta (BBA) - Reviews on Cancer. 2021;1876(1):188587. doi:10.1016/J.BBCAN.2021.188587.
   PubMed Web of Science ®Google Scholar
• Roberti MP, Mordoh J, Levy EM. Biological role of NK cells and immunotherapeutic approaches in breast cancer. Front Immunol. 2012;3(DEC):375. doi:10.3389/fimmu.2012.00375.
   PubMedGoogle Scholar
• Sordo-Bahamonde C, Lorenzo-Herrero S, Payer ÁR, Gonzalez S, López-Soto A. Mechanisms of apoptosis resistance to NK cell-mediated cytotoxicity in cancer. Int J Mol Sci. 2020;21(10):3726. doi:10.3390/IJMS21103726.
   PubMed Web of Science ®Google Scholar